I Love Lund AB Invests in Lead Biologics Growth

In a strategic move that underscores its commitment to innovation in the biotech sector, I Love Lund AB has announced an investment in Lead Biologics International. By acquiring a 4.1% stake, I Love Lund becomes one of the larger shareholders in this promising company. This investment is part of a broader financing round that has successfully raised 6 million SEK, attracting both existing and new investors.

Lead Biologics is at the forefront of developing novel antibody-based immunotherapies aimed at treating cancer, particularly acute myeloid leukemia (AML), a severe form of blood cancer. The company's cutting-edge research has identified three new target molecules that play crucial roles in disease progression and tumor cells' ability to evade the immune system. These discoveries are the foundation for their ongoing development of innovative therapies.

The investment by I Love Lund, alongside Almi Invest Syd AB and several business angels, not only provides financial backing but also brings valuable networking opportunities and advisory support. As Björn Englund, CEO of I Love Lund, expressed, the team at Lead Biologics demonstrates substantial scientific and business acumen, making them a valuable addition to their investment portfolio.

Lead Biologics' CEO, Anki Malmborg Hager, highlighted the synergy between the two companies, both rooted in the innovative environment of Lund. This partnership is expected to foster meaningful collaborations and discussions, leveraging the strengths of both organizations.

For investors, the strategic investment in Lead Biologics by I Love Lund suggests a promising outlook for the company's growth in the life sciences sector. Given the potential of Lead Biologics' therapies to address significant medical needs, investors might consider holding their positions to benefit from future developments.